PNC Financial Services Group Inc. Trims Position in Zoetis Inc. $ZTS

PNC Financial Services Group Inc. decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 4.4% during the 1st quarter, Holdings Channel.com reports. The firm owned 203,999 shares of the company’s stock after selling 9,282 shares during the period. PNC Financial Services Group Inc.’s holdings in Zoetis were worth $24,115,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Brighton Jones LLC grew its holdings in Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after buying an additional 2,978 shares during the period. Empowered Funds LLC lifted its holdings in shares of Zoetis by 6.2% during the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after acquiring an additional 657 shares during the period. Intech Investment Management LLC lifted its holdings in shares of Zoetis by 17.2% during the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after acquiring an additional 1,224 shares during the period. Sivia Capital Partners LLC boosted its position in shares of Zoetis by 73.8% in the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after acquiring an additional 1,422 shares during the last quarter. Finally, Glenview Trust co boosted its position in shares of Zoetis by 11.8% in the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after acquiring an additional 506 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In other Zoetis news, Director Paul Bisaro bought 2,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average price of $75.88 per share, with a total value of $151,760.00. Following the purchase, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael B. Mccallister bought 3,000 shares of Zoetis stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the acquisition, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 11,650 shares of company stock valued at $886,384 over the last 90 days. Corporate insiders own 0.22% of the company’s stock.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Several firms announced or promoted securities-fraud litigation against Zoetis, which can weigh on sentiment by raising legal, financial, and reputational risk for the company. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: The class-action deadline reminders may keep the controversy in the spotlight and encourage more shareholder claims, adding overhang to the stock. ZOETIS CLASS ACTION DEADLINE MONDAY JULY 27th
• Neutral Sentiment: One Seeking Alpha commentary argues Zoetis sentiment remains strong and fundamentals are improving, offering a more constructive longer-term view. Zoetis: Sentiment Keeps Winning As Fundamentals Improve

Zoetis Stock Up 1.0%

Shares of NYSE:ZTS opened at $75.32 on Friday. The stock has a 50-day simple moving average of $77.29 and a 200-day simple moving average of $104.25. The stock has a market capitalization of $31.58 billion, a P/E ratio of 12.49, a PEG ratio of 1.16 and a beta of 0.75. Zoetis Inc. has a 1 year low of $71.47 and a 1 year high of $160.48. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same quarter in the previous year, the business posted $1.48 EPS. The company’s quarterly revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities analysts forecast that Zoetis Inc. will post 6.87 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. Zoetis’s dividend payout ratio is presently 35.16%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ZTS shares. HSBC dropped their price target on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, July 6th. Stifel Nicolaus decreased their price target on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a report on Friday, June 26th. JPMorgan Chase & Co. lowered their price objective on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Argus restated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Finally, Morgan Stanley cut their target price on Zoetis from $115.00 to $99.00 and set an “overweight” rating on the stock in a research report on Wednesday. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $119.50.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.